Latest Fundraising News

AVITA Medical has lodged a new $200 million shelf registration with the SEC, renewing its capacity to issue various securities in the US market. While no immediate capital raising is planned, this move preserves the company’s financial agility for future growth opportunities.

Oneview Healthcare has successfully raised A$19 million through a two-tranche placement and launched a Security Purchase Plan to further strengthen its financial position and accelerate AI development.

Oldfields Holdings Limited remains suspended from ASX trading following its failure to lodge critical half-year financial reports after announcing a capital raising.

ClearVue Technologies reported a 9% reduced half-year loss of $5.25 million, while pushing forward with significant advancements in its solar glass technology and expanding global licensing partnerships.

Keybridge Capital has posted a $6.14 million loss for the half-year ended 31 December 2024, driven by legacy governance issues and significant legal costs. A new board, appointed following court intervention, is now focused on stabilising the company and pursuing recovery actions.

Yowie Group Limited reported a steep 752% increase in its half-year loss to US$4.66 million, amid governance upheaval and impaired loans to its majority shareholder. The company faces ongoing legal and regulatory challenges while pursuing a turnaround.

Activeport Group Ltd reported a 36% revenue decline and a 25% increase in net loss for the half-year ended December 2025, while securing key contracts with Tier 1 telcos and raising $8.8 million in capital.

Dataworks Group Limited reported a significant reduction in its half-year loss alongside a major contract extension in Ontario, marking a pivotal shift to positive cash flow.

Ariadne Australia Ltd reported a modest net profit of $2.8 million for the half-year ended December 2025, underpinned by strong growth in its Orams Group investment and key strategic assets despite foreign exchange headwinds.

Biotron Limited reported a half-year loss as it completed the acquisition of Sedarex Limited and advanced its Hepatitis B drug candidate BIT-HBV001, backed by a $2.5 million capital raise. The company faces material uncertainty over its going concern status, hinging on securing further funding.

Imugene Limited reports a narrower half-year loss as it advances its promising azer-cel CAR T therapy with strong clinical results and FDA backing, supported by a $25 million capital raise.

Epiminder Limited has reported a $21.7 million loss for the half-year ending December 2025, alongside a successful $125 million IPO that fuels its commercialisation of the FDA-approved Minder epilepsy monitoring device.